Trial Profile
A Phase I, Multiple-dose study to access the Safety, tolerability and pharmacokinetics of Ombitasvir/paritaprevir/ritonavir and Dasabuvir in Healthy Han Chinese Subjects residing in USA
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jul 2018
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- 10 Jul 2018 New trial record
- 16 Jun 2018 Results assessing the Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy and HCV GT1b-Infected Chinese, Korean and Taiwanese Patients from NCT02534870, NCT02517515, NCT02517528 and one more study, published in the European Journal of Drug Metabolism and Pharmacokinetics